# SEP 2 4 2008

As required by 21 CFR Section 807.92(c).

Submitted by:

Cepheid 904 Caribbean Drive Sunnyvale, CA 90489 Phone number: (408) 400-8230 Fax number: (408) 541-6439

# Contact:

Date of Preparation:

Russel K. Enns, Ph.D. September 19, 2008

Device: Trade name: Common name:

Xpert MRSA/SA SSTI Assay

Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) from skin and soft tissue infections Assay.

Type of Test:

Nucleic Acid Amplification Test, DNA, Staphylococcus aureus (SA) and Methicillin-resistant Staphylococcus aureus (MRSA), qualitative

Panel:

83

Predicate Device:

Cepheid Xpert MRSA Assay [510(k) no. K070462]

Device Description:

The Cepheid Xpert MRSA/SA Skin and Soft Tissue Infection Assay (Xpert MRSA/SA SSTI Assay) is a rapid, automated DNA test for simultaneously detecting MRSA and SA directly from skin and soft tissue specimcns. The specimen is collected on a double swab, which is placed in a tube containing elution reagent. Following brief vortexing, the eluted material and two single-use reagents (Reagent 1 and Reagent 2) that are provided with the assay are transferred to different, uniqucly-labeled chambers of the disposable fluidic cartridge (the Xpert MRSA/SA cartridge). The user initiates a test from the system user interface and places the cartridge into the GeneXpert $\textsuperscript { \textregistered }$ Dx System instrument platform, which performs hands-off real-time, multiplex polymerase chain reaction (PCR) for detection of DNA. In this platform, additional sample preparation, amplification, and real-time detection are all fully-automated and completely integrated.

The GeneXpert $\textsuperscript { \textregistered }$ System consists of a GeneXpert instrument, personal computer, and the multi-chambered fluidic cartridges that are designed to complete sample preparation and real-time PCR for detection of MRSA and SA in approximately 50 minutes. Each system has 1 to 16 randomly accessible modules that are each capable of performing separate sample preparation and real-time PCR tests. Each module contains a syringe drive for dispensing fluids, an ultrasonic horn for lysing cells or spores, and a proprietary ICORE $\textsuperscript { \textregistered }$ thermocycler for performing real-time PCR and detection.

The Xpert MRSA/SA Assay includes reagents for the simultaneous detection of the target organisms, SA and MRSA. The primers and probes in the Xpert MRSA/SA Assay detect nucleic acid sequences of the staphylococcal protein A $( s p a )$ , the gene for MecAMediated Oxacillin resistance (mecA), and staphylococcal cassette chromosome (SCCmec) inserted in the SA chromosomal attB site.

The test includes a sample processing control (SPC) to control for adequate processing of the target bacteria and to monitor the presence of inhibitor(s) in the PCR assay. The Probe Check Control (PCC) verifies reagent rehydration, PCR tube filling in the cartridge, probe integrity, and dye stability.

# Device Intended Use:

The Cepheid Xpert MRSA/SA Skin and Soft Tissues Infection Assay (Xpert MRSA/SA SSTI Assay) performed in the GeneXpert® Dx System is a qualitative in vitro diagnostic test intended for the detection of Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) from skin and soft tissue infection swabs. The test utilizes automated real-time polymerase chain reaction (PCR) to detect MRSA/SA DNA. The Xpert MRSA/SA SSTI Assay is indicated for use in conjunction with other laboratory tests such as microbiology culture, and clinical data available to the clinician as an aid in the detection of MRSA/SA from skin and soft tissue infections. The Xpert MRSA/SA SSTI Assay is not intended to monitor treatment for MRSA/SA infections. Concomitant cultures for SA and MRSA are necessary to recover organisms for susceptibility testing or epidemiological typing.

In a mixed culture containing MRSA/SA and other organisms (e.g. Gram ncgative bacilli, yeast), results can be false negative or variable depending on the concentration of MRSA/SA present, particularly if the concentration of MRSA/SA is close to the LoD of the assay.

Substantial Equivalence:

The Xpert MRSA/SA SSTI Assay is substantially equivalent to two molecular-based MRSA and SA assays, Cepheid XpertTM MRSA Assay (K070462) and the BD GeneOhm StaphSR Assay (K071026). All three assays detect MRSA and the Xpert MRSA/SA and the BD GeneOhm StaphSR Assay detect both SA and MRSA; all three assays determine the presence of the target organisms through real-time PCR amplification and fluorogenic target-specific hybridization detection. Both Cepheid assays utilize the same fullyautomated instrument system, the Cepheid GeneXpert Dx System.

The Xpert MRSA/SA SSTI Assay simultaneously detects SA and MRSA from skin and soft tissue specimens. The Xpert MRSA Assay detects MRSA from nasal swab specimens. The BD GeneOhm StaphSR Assay detects SA and MRSA from positive blood cultures. Table 5.1 shows the similarities and differences between the Xpert MRSA/SA SSTI Assay and the two molecular-based predicate devices.

The Xpert MRSA/SA SSTI is also substantially equivalent to conventional microbiologybased predicate devices that identify (ID) and/or test for antimicrobial susceptibility (AST) of gram positive organisms, including Staphylococcus species of human origin from pure culture isolates. These conventional microbiology-based predicates accommodate multiple specimen types, including swabbed specimens of skin and soft tissue infections. These conventional microbiology-based predicates are:

•Remel Staphaurex Latex Agglutination Test (K851949), BBL (BD) Oxacillin Screen Agar (K863821),   
BD BBL CHROMagar MRSA (K042812   
BD Phoenix Automated Microbiology ID/AST System (K020322 and K023301).

Table 5.2 compares the new device with the conventional microbiology-based assays for SA. Table 5.3 compares the new device with the conventional microbiology-based assays for MRSA.

A multi-center study was conducted on 848 patients to determine the performance characteristics of the device relative to the sensitivity and specificity of culture and susceptibility testing, the current standard of care. The test results showed the Xpert MRSA/SA SSTI to be substantially equivalent to the current standard of care, identification of Staphyloccoccus aureus from solid media by catalase, coagulase, and Gram stain, and susceptibility by cefoxitin disk diffusion test.

Table 5.1 Similarities and Differences Between the Xpert MRSA/SA SSTI Assay and the Molecular-based Predicate Devices   

<table><tr><td colspan="4" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Device</td><td colspan="2" rowspan="1">Predicates</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Xpert MRSA/SA SSTI Assay</td><td colspan="1" rowspan="1">Xpert MRSAAssay(K070462)</td><td colspan="1" rowspan="1">BD GeneOhmTMStaphSR Assay(K071026)</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Rapid detection of MRSA andSA</td><td colspan="1" rowspan="1">MRSA only</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Indication for Use</td><td colspan="1" rowspan="1">Identification of MRSA and SA</td><td colspan="1" rowspan="1">MRSA only</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">TechnologicalPrinciples</td><td colspan="1" rowspan="1">Fully-automated nucleic acidamplification (DNA); real-timePCR</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Test Cartridge</td><td colspan="1" rowspan="1">Disposable single-use, multi-chambered fluidic cartridge.</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Disposablesingle-use PCRtube</td></tr><tr><td colspan="1" rowspan="1">Instrument System</td><td colspan="1" rowspan="1">Cepheid GeneXpert Dx System</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">CepheidSmartCycler</td></tr><tr><td colspan="1" rowspan="1">Fluidics</td><td colspan="1" rowspan="1">Self-contained and automatedafter swab elution and twosingle-dose reagent additions.</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Manual</td></tr><tr><td colspan="1" rowspan="1">Probes</td><td colspan="1" rowspan="1">TaqMan® Probes</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">MolecularBeacons</td></tr><tr><td colspan="1" rowspan="1">Internal Controls</td><td colspan="1" rowspan="1">Sample processing control(SPC) and probe check control(PCC).</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">One internalreagent controland externalpositive andnegative controlsrequircd per run</td></tr><tr><td colspan="1" rowspan="1">DNA TargetSequence</td><td colspan="1" rowspan="1">Sequence incorporating theinsertion site (attBssc) ofStaphylococcal CassetteChromosome mec (SCCmec)for detection of MRSA.</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Sequence specific tomethicillin/oxacillin resistance(mecA gene)</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1">Rapid test results</td><td colspan="1" rowspan="1">Approximately 50 minutes toresults.</td><td colspan="1" rowspan="1">Approximately75 minutes toresults.</td><td colspan="1" rowspan="1">Approximately60-75 minutes.</td></tr><tr><td colspan="1" rowspan="1">Users</td><td colspan="1" rowspan="1">Operators with no clinical labexperience to experiencedclinical laboratorytechnologists.</td><td colspan="1" rowspan="1">Same.Categorized asa CLIAmoderatecomplexityassay.</td><td colspan="1" rowspan="1">CLIA HighComplexityLaboratory Users</td></tr></table>

Table 5.2   

<table><tr><td rowspan=1 colspan=4>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=2>Predicates</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Xpert MRSA/SA SSTI Assay</td><td rowspan=1 colspan=1>Xpert MRSAAssay(K070462)</td><td rowspan=1 colspan=1>BD GeneOhmTMStaphSR Assay(K071026)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Simultaneous rapid detection ofSA and MRSA.</td><td rowspan=1 colspan=1>Only detectsMRSA.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Direct from skin and soft tissueinfection swabs.</td><td rowspan=1 colspan=1>Direct fromnasal swabs.</td><td rowspan=1 colspan=1>Direct fromPositive BloodCultures</td></tr><tr><td rowspan=1 colspan=1>DNA TargetSequence</td><td rowspan=1 colspan=1>Sequence specific toStaphylococcus aureus species(spa gene)</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>Sequencespecific toStaphylococcusaureus species(nuc genc)</td></tr><tr><td rowspan=1 colspan=1>Ability to identifycorrectly &quot;EmptyCassette Variants&quot;</td><td rowspan=1 colspan=1>Yes, sequence specific toStaphylococcus aureus species(mecA gene)</td><td rowspan=1 colspan=1>No</td><td rowspan=1 colspan=1>No</td></tr></table>

# Similarities and Differences Betwcen the Xpert MRSA/SA SSTI Assay and the Conventional Microbiology-based Predicate Devices for

Staphylococcus aureus (SA) only

<table><tr><td colspan="3">Similarities</td></tr><tr><td>Item</td><td>Device</td><td>Predicates (SA only)</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Xpert MRSA/SA SSTIAssay</td><td rowspan=1 colspan=1>StaphaurexLatexAgglutinationTest for SAK851949</td><td rowspan=1 colspan=1>BD PhoenixAutomatedMicrobiologySystem for SAK020322</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Detection of SA</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Single use</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Controls</td><td rowspan=1 colspan=1>Positive Control: SANegative Control: S.epidermidis</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=4>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=2>Predicates (SA only)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Xpert MRSA/SA SSTIAssay</td><td rowspan=1 colspan=1>StaphaurexLatexAgglutinationTest for SAK851949</td><td rowspan=1 colspan=1>BD PhoenixAutomatedMicrobiologySystem for SAK020322</td></tr><tr><td rowspan=1 colspan=1>Mode ofDetection</td><td rowspan=1 colspan=1>Sequence specific toStaphylococcus aureusspecies (spa gene)</td><td rowspan=1 colspan=1>Clumping factorand protein A</td><td rowspan=1 colspan=1>Microbialutilization anddegradation ofspecificsubstrates</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Direct from skin and softtissue infection swabs.</td><td rowspan=1 colspan=1>Staphylococcusspecies</td><td rowspan=1 colspan=1>Gram Positiveorganisms</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Amplification: PCRDetection: Fluorogenic target-specific hybridization</td><td rowspan=1 colspan=1>Agglutinationwith latexparticlessensitized withfibrinogen andIgG</td><td rowspan=1 colspan=1>Conventional,chromogenic andfluorogenicbiochemical testsfor identification(D)andantimicrobialresistance test(AST)</td></tr><tr><td rowspan=1 colspan=1>Interpretation oftest results</td><td rowspan=1 colspan=1>Diagnostic software of theGeneXpert Dx System</td><td rowspan=1 colspan=1>Visualinterpretation</td><td rowspan=1 colspan=1>Automated</td></tr></table>

# Table 5.3

# Similarities and Differences Between the Xpert MRSA/SA SSTI Assay and the Conventional Microbiology-based Predicate Devices for

Methicillin-Resistant Staphylococcus aureus (MRSA)

<table><tr><td rowspan=1 colspan=5>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=3>Predicates (MRSA only)</td></tr><tr><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>XpertMRSA/SA SSTIAssay</td><td rowspan=1 colspan=1>MuellerHinton Agarw/ 4% NaCland Oxacillin(OxacillinScreen AgarTest)K863821</td><td rowspan=1 colspan=1>BBLCHROMagarMRSA(K042812)</td><td rowspan=1 colspan=1>BD PhoenixAutomatedMicrobiologySystemK023301</td></tr><tr><td rowspan=1 colspan=1>IntendedUse</td><td rowspan=1 colspan=1>Detection ofMRSA</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Single use</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>AssayControls</td><td rowspan=1 colspan=1>Positive Control:MRSANegative Control:SA</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td colspan="5" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="3" rowspan="1">Predicates (MRSA only)</td></tr><tr><td colspan="1" rowspan="1">b</td><td colspan="1" rowspan="1">XpertMRSA/SA SSTIAssay</td><td colspan="1" rowspan="1">MuellerHinton Agarw/ 4% NaCland Oxacillin(OxacillinScreen AgarTest)K863821</td><td colspan="1" rowspan="1">BBLCHROMagarMRSA(K042812)</td><td colspan="1" rowspan="1">BD PhoenixAutomatedMicrobiologySystemK023301</td></tr><tr><td colspan="1" rowspan="1">Mode ofDetectionformethicillinresistance</td><td colspan="1" rowspan="1">SCCmec genespecific forMRSAmecA genespecific formethicillin/oxacillinresistance</td><td colspan="1" rowspan="1">Growth onMueller HintonAgar with 4%NaCl and 6 ug/mloxacillin</td><td colspan="1" rowspan="1">Use of specificChromogenicsubstrates andcefoxitin todifferentiateMRSA fromother organisms</td><td colspan="1" rowspan="1">Utilizes aredox indicatorfor detection oforganismgrowth in thepresence of anantimicrobialagent</td></tr><tr><td colspan="1" rowspan="1">SpecimenType</td><td colspan="1" rowspan="1">Direct from skinand soft tissueinfection swabs.</td><td colspan="1" rowspan="1">Pure cultureisolate ofStaphylococcusaureus</td><td colspan="1" rowspan="1">Direct fromAnterior nares</td><td colspan="1" rowspan="1">Pure cultureisolate ofStaphylococcusaureus</td></tr><tr><td colspan="1" rowspan="1">Assayformat</td><td colspan="1" rowspan="1">Amplification:PCRDetection:Fluorogenictarget-specifichybridization</td><td colspan="1" rowspan="1">Phenotypicdetection basedon a 24 hourgrowth of SAinoculated onmedia</td><td colspan="1" rowspan="1">Phenotypicdetection baseon a 24-48 hourgrowth of SA(mauvecolonies)inoculated onmedia</td><td colspan="1" rowspan="1">AST panclscontainingMIC tests forseveralantimicrobialagents</td></tr><tr><td colspan="1" rowspan="1">Interpretation of testresults</td><td colspan="1" rowspan="1">Diagnosticsoftware of theGeneXpert DxSystem</td><td colspan="1" rowspan="1">Manual: Visualinterpretation</td><td colspan="1" rowspan="1">Manual: Visualinterpretation</td><td colspan="1" rowspan="1">Automated</td></tr></table>

Non-Clinical Studies:

# Analytical Inclusivity Study on CDC Staphylococcus aureus Specimens

The analytical inclusivity of the Xpert MRSA/SA Assay was determined using Staphylococcus aureus strains that were reported by the Center for Disease Control (CDC) to be representative of MRSA and MSSA strains currently encountered in the healthcare community. All strains were tested in triplicate using $1 0 0 \mu \mathrm { L }$ of stationary phase cell suspensions diluted 10 million-fold. The panel consisted of MRSA strains representing SCCmec types II, IV, IVa, IVb, and IVc in addition to several unknown types. Data supplied by the Center for Disease Control (CDC) indicated these strains, when characterized by pulsed-field gel electrophoresis (PFGE), represent numerous USA types including USA100, the most common hospital-acquired strain and USA300 and USA400, the most common community-acquired strains.'

All 21 MRSA strains were correctly reported MRSA positive; SA positive using the Xpert MRSA/SA Assay. Additionally, each MSSA strain $( \mathtt { n } \mathtt { = } 3 )$ was correctly reported MRSA negative; SA positive. Culture using BBL CHROMagar MRSA confirmed all Xpert test results. Colony forming units per assay were determined by plate counts in duplicate.

# Analytical Inclusivity Study on Expanded Panel of Staphylococcus aureus Specimens

One hundred twenty-onc (121) additional Staphylococcus aureus strains were tested using the Xpert MRSA/SA Assay. Overnight cultures were grown in Brain Heart Infusion (BHI) broth and adjusted to 0.5 McFarland units. All strains were tested in triplicate using $1 0 0 ~ \mu \mathrm { L }$ of cultures further diluted 100 thousand to one million-fold.

MRSA (78) and SA (43) strains were selected to broadly represent the range of genetic diversity found in the species Staphylococcus aureus based on phylogenetic structure. Selections represent primary lineages with emphasis on specific clonal complexes within which MRSA is predominantly observed. Lineages that contain MRSA and SA, as well as those that contain SA exclusively were included.

The Xpert MRSA/SA Assay correctly identified 116 of 121 strains. The 5 discordants were characterized by catalase, tube coagulase, and Gram stain. MecA-Mediated Oxacillin resistance was asscssed by disk diffusion using a $3 0 ~ \mu \varrho$ cefoxitin disk and a diameter cut-off of $2 1 / 2 2 \mathrm { m m }$ .

Three (3) of 78 MRSA strains were reported MRSA negative; SA positive using the Xpert assay. Further characterization indicates these strains are not resistant and were correctly reported MRSA negative; SA positive.

Two (2) of 43 SA strains were reported MRSA positive; SA positive using the Xpert assay. Further characterization indicates these strains are resistant and were correctly reported MRSA negative; SA positive.

Each of the 12 known USA300 isolates were correctly reported MRSA positive and SA positive as expected.

# Evaluation of Empty Cassette Variants

Twenty-two (22) Staphylococcus aureus isolates identified as "empty cassette variants" were tested using the Xpert MRSA/SA Assay. Overnight cultures were adjusted to 0.5 McFarland units. All strains were tested from cultures further diluted 100-fold (high) and 100 thousand-fold (low).

The Xpert MRSA/SA Assay correctly identified all 22 isolates as MRSA negative and SA positive. At both cell concentrations tested, only Cts for the spa and SCCmec targets were reported. No mecA Cts were reported

# Analytical Sensitivity Limit of Detection Studies

Studics were performed to determine the $9 5 \%$ confidence intervals for the analytical limit of detection (LoD) of Staphylococcus aureus (SA) cells and methicillin-resistant Staphylococcus aureus (MRSA) cells diluted into a surrogate wound matrix of human origin. The surrogate wound matrix consisted of a white blood cell (WBC) concentrate prepared from whole blood by centrifugation. The matrix also contained red blood cells (RBC) and plasma, and a negligible amount of anticoagulant (CPD or CPDA-1). The limit of detection is defined as the lowest number of colony forming units (CFU) per sample that can be reproducibly distinguished from negative samples with $9 5 \%$ EPY confidence or the lowest concentration at which 19 of 20 replicates were positive.

For MRSA, replicates of 20 were evaluated at each MRSA concentration tested (CFU/swab) for 6 individual isolates representing SCCmec types I, II, III, IVa, V, and VI. When characterized by pulsed-field gel electrophoresis (PFGE), USA100, the most common healthcare-acquired strain and USA400, one of the most common communityacquired strains were represented.

For SA, replicates of 20 were evaluated at each SA concentration (CFU/swab) for 3 individual SA isolates. USA types USA900 and USA1200 werc represented.

The estimate and confidence intervals were determined using logistic regression with data (number of positive results per number of replicates at each level) over the range of CFU/swab tested. The confidence intervals were determined using maximum likelihood estimates on the logistic model parameters using the large sample variance-covariance matrix. The LoD point estimates and $9 5 \%$ upper and lower confidence intervals for each SA and each MRSA SCCmec type tested are summarized in Tables 5.4 and 5.5.

![](images/b45357f0e5cbead2a986ae3243b55f1c189fffa80e715cb2b7ba4fa22333587f.jpg)  
Table 5.4: LoD and Confidcnce Intervals - SA

Table 5.5: LoD and Confidence Intervals - MRSA   

<table><tr><td>MRSA Strain ID</td><td colspan="4">SCCmec Type</td><td colspan="2">PFGE</td><td colspan="2">LoD Lower (CFU/swab)</td><td></td><td>Upper</td></tr><tr><td>w</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>95% CI</td><td>95% CI</td><td></td></tr><tr><td>64/4176</td><td></td><td></td><td></td><td></td><td></td><td>USA500</td><td>221</td><td>195</td><td>271</td><td></td></tr><tr><td>N315</td><td></td><td>II</td><td></td><td></td><td></td><td>USA100</td><td>122</td><td>106</td><td>152</td><td></td></tr><tr><td>11373</td><td></td><td>III</td><td></td><td></td><td></td><td>unknown</td><td>124</td><td>115</td><td>155</td><td></td></tr><tr><td>MW2</td><td></td><td>IVa</td><td></td><td></td><td></td><td>USA400</td><td>82</td><td>68</td><td>113</td><td></td></tr><tr><td>ST59-MRSA-V</td><td>V</td><td></td><td></td><td></td><td>USA1000</td><td>242</td><td></td><td>208</td><td>305</td><td></td></tr><tr><td>HDE288</td><td>VI</td><td></td><td></td><td></td><td>USA800</td><td>183</td><td></td><td>161</td><td>223</td><td></td></tr><tr><td>64/4176</td><td>I</td><td></td><td></td><td></td><td>USA500</td><td>221</td><td></td><td>195</td><td>271</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>

The results of this study indicate that the Xpert MRSA/SA SSTI Assay will produce a positive SA result $9 5 \%$ of the time with $9 5 \%$ confidence for a wound swab containing 123 CFU and a positive MRSA result $9 5 \%$ of the time with $9 5 \%$ confidence for a wound swab containing 300 CFU.

# Linearity

A study was conducted to define the reportable range of the Xpert MRSA/SA Assay and demonstrate a linear relationship between SA and MRSA input and assay output (Ct). Linearity was evaluated using ten-fold serial dilutions (1e8 CFU/sample — 10 CFU/sample) of SA and MRSA isolates.

The Xpert MRSA/SA Assay responds linearly $( \mathrm { r } ^ { 2 } = 0 . 9 9 8 )$ with respect to spa detection as a function of SA cell input over 6 logs. The mean reportable Ct range $= 1 3 . 4$ to 33.1. PCR efficiency for the spa reaction is $100 \%$

The Xpert MRSA/SA Assay responds linearly $( \mathbf { r } ^ { 2 } = 0 . 9 9 9 )$ with respect to spa detection as a function of MRSA cell input over 6 logs. The mean reportable Ct range $\approx 1 4 . 3$ to 35.0. PCR efficiency for the spa reaction is $9 5 . 4 \%$ .

The Xpert MRSA/SA Assay responds linearly $( \mathbf { r } ^ { 2 } = 0 . 9 9 9 )$ with respect to mecA detection as a function of MRSA cell input over 6 logs. The mean reportable Ct range $= 1 4 . 2$ to 35.3. PCR efficiency for the mecA reaction is $9 3 . 3 \%$ .

The Xpert MRSA/SA Assay responds linearly $( \mathrm { r } ^ { 2 } = 0 . 9 9 9 )$ with respect to SCCmec detection as a function of MRSA cell input over 5 logs. The mean reportable Ct range for SCCmec is 16.6 to 33.8. PCR efficiency for the mec reaction is $9 4 . 6 \%$ E

# Analytical Specificity

# Cross-reactivity Study

One hundred five (105) strains were collected, quantitated and tested using the Xpert MRSA/SA Assay. The 98 cultures from the American Type Culture Collection (ATCC) and 7 strains from the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) represent species phylogenetically related to Staphylococcus aureus or those potentially encountered in a hospital environment.

Of these, methicillin-sensitive coagulase negative staphylococci (29) and methicillinresistant coagulase negative staphylococci (9) were included. The organisms tested were identified as either Gram positive (74), Gram negative (28), or yeast (3). The organisms were further classified as either aerobic (95) or anaerobic (10).

Two (2) or more replicates of each isolate were tested at 1.7 - 3.2 McFarland units. Under the conditions of the study, all isolates were reported MRSA negative and SA negative; none of the isolates were detected by the Xpert MRSA/SA Assay. Positive and Negative controls were included in the study. The analytical specificity was $1 0 0 \%$

# Evaluation of BORSA Strains

Seven (7) well characterized borderline oxacillin-resistant Staphylococcus aureus (BORSA) strains were tested, including one apparent "empty cassette" (see above). Methicillin-resistant Staphylococcus aureus is resistant to al B-lactam drugs through the alternative penicillin-binding protein PBP2a encoded by mecA15. BORSA strains are mecA negative, but exhibit an oxacillin minimum inhibitory concentration $\mathrm { ( M C ) } \geq 2$ and $\leq 8 \mu \mathrm { g / m L }$ . It is especially valuable to distinguish MRSA from BORSA to prevent the unnecessary and inappropriate use of vancomycin and isolation precautions not warranted for patients infected with a B-lactam susceptible strain16.

Under the conditions of this study, all 7 BORSA isolates (including the apparent "empty cassette" isolate) were reported MRSA negative; SA positive at both high and low cell concentrations using the Xpert MRSA/SA Assay. No mecA signals were reported. These results demonstrate that a BORSA strain will be correctly identified as MRSA negative; SA positive and will not report a false positive MRSA test result using the Xpert MRSA/SA Assay.

# Interfering Substances

In the investigational study for Xpert MRSA/SA SSTI Assay, 428 of thc 848 specimens were observed to contain blood, and 404 were observed to contain other non-specific substances, which could potentially interfere with the assay (note that some specimens contained more than one type of potential contaminant). Fisher's exact tests conducted on the data generated from swabs with and without these potential interfering substances demonstrated that their presence did not affect the assay performance.

In a non-clinical study, potentially interfering substances that may be present in clinical skin and soft tissue infection specimens were evaluated directly relative to the performance of the Xpert MRSA/SA Assay. Potentially interfering substances in skin and soft tissue infections may include, but are not limited to: blood, pus, plasma, topical ointments (antibiotic/antiseptic/pain relieving), debriding agents, and tinctures. These substances are listed in Table 5.6a and Table 5.6b with the active ingredients and concentrations tested shown. Inhibition of the MRSA/SA assay has been observed with the following substances: StaphA $+$ Septic $( 5 \% \mathrm { w / v } )$ , Hydrocortisone $( 5 \% \mathrm { w } / \mathrm { v } )$ , and antibacterial hand sanitizer $( 5 \% \mathrm { w / v } )$ .

Table 5.6a: Potentially Interfering SSTI Substances Tested   

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Active Ingredient</td><td rowspan=1 colspan=1>% Tested</td></tr><tr><td rowspan=1 colspan=1>TET Buffer (control)</td><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>Control</td></tr><tr><td rowspan=1 colspan=1>Buffy Coat (woundstimulant)</td><td rowspan=1 colspan=1>WBC (1.5e9/mL)</td><td rowspan=1 colspan=1>50% (v/v)</td></tr><tr><td rowspan=1 colspan=1>Whole Blood (MRSA/SAfrec)</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>50% (v/v)</td></tr><tr><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>50% (v/v)</td></tr><tr><td rowspan=1 colspan=1>Neosporin</td><td rowspan=1 colspan=1>400 units Bacitracin5,000 units Polymyxin B3.5 mg Neomycin</td><td rowspan=1 colspan=1>1% and5% (w/v)</td></tr><tr><td rowspan=1 colspan=1>StaphA*Septic</td><td rowspan=1 colspan=1>0.2% BenzethoniumChloride, 2.5% LidocaineHCl</td><td rowspan=1 colspan=1>1% and5% (w/v)</td></tr><tr><td rowspan=1 colspan=1>Hyrdocortisone</td><td rowspan=1 colspan=1>1% Hyrdocortisone</td><td rowspan=1 colspan=1>1% and5% (w/v)</td></tr><tr><td rowspan=1 colspan=1>Biol-Ease</td><td rowspan=1 colspan=1>20% Benzocaine</td><td rowspan=1 colspan=1>1% and5% (w/v)</td></tr><tr><td rowspan=1 colspan=1>Iodine Tincture</td><td rowspan=1 colspan=1>2% lodine</td><td rowspan=1 colspan=1>50% (v/v)</td></tr></table>

Table 5.6b: Potential Interfering SSTI Substances Tested   

<table><tr><td colspan="1" rowspan="1">Substance</td><td colspan="1" rowspan="1">Active Ingredient</td><td colspan="1" rowspan="1">% Tested</td></tr><tr><td colspan="1" rowspan="1">TET Buffer(control)</td><td colspan="1" rowspan="1">Control</td><td colspan="1" rowspan="1">Control</td></tr><tr><td colspan="1" rowspan="1">Mupirocin</td><td colspan="1" rowspan="1">0.2% BenzethoniumChloride 2.5% LidocaineHCI</td><td colspan="1" rowspan="1">5% (w/v)</td></tr><tr><td colspan="1" rowspan="1">Saline</td><td colspan="1" rowspan="1">0.65% Sodium Chloride</td><td colspan="1" rowspan="1">50% (v/v)</td></tr><tr><td colspan="1" rowspan="1">Antibacterial handsanitizer</td><td colspan="1" rowspan="1">62% Ethyl alcohol</td><td colspan="1" rowspan="1">1% (w/v)</td></tr><tr><td colspan="1" rowspan="1">Antibacterial handsanitizer</td><td colspan="1" rowspan="1">62% Ethyl alcohol</td><td colspan="1" rowspan="1">5% (w/v)</td></tr><tr><td colspan="1" rowspan="1">70% Isopropylalcohol</td><td colspan="1" rowspan="1">70% Isopropyl alcohol</td><td colspan="1" rowspan="1">50% (v/v)</td></tr></table>

# Clinical Studies

# Performance Characteristics

# Clinical Performance

Performance characteristics of the Xpert MRSA/SA SSTI Assay were determined in a multi-site prospective investigation study at four US institutions by comparing the Xpert MRSA/SA SSTI Assay with reference culture. Subjects included individuals whose routine care called for collection of a swab from the patient's skin and soft tissue infection for culture.

Double swabs were collected from each subject. One swab was tested by the Xpert MRSA/SA SSTI Assay at the enrolling center and the other swab was tested by the site's standard method, and the remaining specimen was sent to the central laboratory for reference culture testing.

At the centralized laboratory, the specimen was enriched overnight in trypticase soy broth with $6 . 5 \%$ NaCl. The trypticase soy broth was then streaked onto plates with cefoxitin (for MRSA) and without cefoxitin (for SA). If either or both the SA or MRSA plates showed S. aureus presumptive colonies, the colonies were sub-cultured onto a blood agar plate. Confirmation of presumptive positive colonies was performed with catalase, tube coagulase, and Gram stain. MecA-Mediated Oxacillin resistance was tested by disk diffusion test using a $3 0 ~ \mu \mathbf { g }$ cefoxitin disk and cutoff of $2 1 / 2 2 \mathrm { m m }$ .If the cultures for both the SA and MRSA plates were determined to be negative, the archived trypticase soy broth with $6 . 5 \%$ NaCl was subcultured onto blood agar followed by workup for SA/MRSA as previously described.

Performance of the Xpert MRSA/SA SST1 Assay was calculated relative to the reference culture results.

# Overall Results

A total of 848 specimens were tested for MRSA and SA by Xpert MRSA/SA SSTI Assay and culture.

Among the 848 cases in the eligible dataset, antibiotic use within the 3 weeks prior to sample collection was reported for 207 subjects, and no antibiotic use was confirmed for 441 subjects; for 200 cases, antibiotic status was unknown. A statistically significant decrease in the positivity rate of SA with respect to culture results was observed when antibiotics were used $( { \tt p } ^ { = } 0 . 0 0 7 )$ ); this phenomenon has also been reported in the lesser extent $( \mathfrak { p } ^ { = 0 . 0 2 2 } ,$ . The decrease in positivity was not observed with the Xpert MRSA/SA Assay when antibiotics were used nor was any inhibition observed in the assay in the presence of topical antibiotics (see Interfering Substances). The decreased culture positivity rates for MRSA and SA in the presence of antibiotics caused the higher than expected false positive rates observed with the Xpert MRSA/SA SSTI Assay.

Five (5) of thc 246 MRSA positive cultures had mixed infections of MRSA and SA. Xpert MRSA/SA SSTI identificd 3 of the 5 mixed infections as MRSA positive and 2 of the five as SA positive/MRSA negative.

The performance of the Xpert MRSA/SA SSTI Culture Assay is summarized in Tables 5.7a-5.7c.

Table 5.7a: MRSA/SA Performance in Subjects with No Antibiotic Use (within 3 weeks of sample collection) vs. Reference Culture   
Culture   

<table><tr><td rowspan=5 colspan=2>MRSA+pedn   SA+/MRSA-SA-Total</td><td rowspan=1 colspan=1>MRSA+</td><td rowspan=1 colspan=1>SA+/MRSA-</td><td rowspan=1 colspan=1>Neg/No Growth</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>MRSA+</td><td rowspan=1 colspan=1>137a</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>145</td></tr><tr><td rowspan=1 colspan=1>SA+/MRSA-</td><td rowspan=1 colspan=1>$3b}$</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>98</td></tr><tr><td rowspan=1 colspan=1>SA-</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>198</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>146</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>210</td><td rowspan=1 colspan=1>441</td></tr></table>

$^ { \mathbf { a } } 1$ of the 137 were mixed infcctions of MRSA and SA. ${ \mathsf b } _ { 2 }$ of the 3 were mixed infections of MRSA and SA. Positive Percent Agreement $( \mathrm { M R S A } + ) = 9 3 . 8 \% ;$ $9 5 \% \mathrm { C }$ onfidence Interval $= 8 8 . 6 { \cdot } 9 7 . 1 $ EMPY Negative Percent Agreement $( \mathrm { M R S A } + ) = 9 7 . 3 \%$ $9 5 \%$ Confidence Interval $\underline { { \mathbf { \Pi } } } = 9 4 . 7 – 9 8 . 8 $ EY Positive Percent Agreement $( \mathrm { S A } { + } / \mathrm { M R S A } { + } ) = 9 5 . 7 \%$ $9 5 \%$ Confidence Interval $= 9 2 . 2 \cdot$ 97.9 Negative Percent Agreement $( \mathrm { S A } { + } / \mathrm { M R S A } { + } ) = 8 9 . 5 \%$ $9 5 \%$ Confidence Interval $= 8 4 . 6 \AA$ 93.3

Among subjects with no antibiotic use within the 3 weeks prior to sample collection, the Xpert MRSA/SA SSTI Assay identified $9 3 . 8 \%$ of the specimens positive for MRSA and $9 7 . 3 \%$ of the specimens negative for MRSA relative to the reference culture method, and

$9 5 . 7 \%$ of the specimens positive for SA and $8 9 . 5 \%$ of the specimens negative for SA relative to the reference culture method.

Among these subjects with no antibiotic use, $9 6 . 8 \%$ (427/441) were successful on the first attempt with the Xpert MRSA/SA Assay. The remaining 14 gave indeterminate results on the first attempt (6 "INVALID", 7 "ERROR" and 1 "NO RESULT"). Of the 14 indeterminate on the first attempt, all gave a result on the second attempt.

Table 5.7b: MRSA/SA Performance in Subjects with Unknown Antibiotic Use (within 3 weeks of sample collection) vs. Referencc Culture   
Culture   
  

<table><tr><td rowspan=5 colspan=2>MRSA+SA+/MRSA-SA-Total</td><td rowspan=1 colspan=1>MRSA+</td><td rowspan=1 colspan=1>SA+/MRSA-</td><td rowspan=1 colspan=1>Neg/No Growth</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>MRSA+</td><td rowspan=1 colspan=1>47c</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>51</td></tr><tr><td rowspan=1 colspan=1>SA+/MRSA-</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>55</td></tr><tr><td rowspan=1 colspan=1>SA-</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>91</td><td rowspan=1 colspan=1>94</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>200</td></tr></table>

$^ \circ 2$ of the 47 were mixed infections of MRSA and SA. Positive Percent Agreement $( \mathrm { M R S A ^ { + } } ) = 9 4 . 0 \% ;$ $9 5 \% \mathrm { C }$ onfidence Interval $= 8 3 . 5 { \cdot } 9 8 . 7 $ Negative Percent Agreement $( \mathrm { M R S A } { + } ) = 9 7 . 3 \%$ .. $9 5 \% C$ onfidence Interval $= 9 3 . 3 – 9 9 . 3$ EY Positive Percent Agreement $( \mathrm { S A } { + } / \mathrm { M R S A } { + } ) = 9 6 . 9 \%$ . $9 5 \%$ Confidence Interval $= 9 1 . 2 \cdot$ 99.4 Negative Percent Agreement $( \mathrm { S A } { + } / \mathrm { M R S A } { + } ) = 8 8 . 3 \%$ $9 5 \% \mathrm { C }$ onfidence Interval $= 8 0 . 5 \AA$ 93.8

When it was unknown if subjects took antibiotics within the 3 weeks prior to sample collection, the Xpert MRSA/SA SSTI Assay identified $9 4 . 0 \%$ of the specimens positive for MRSA and $9 7 . 3 \%$ of the specimens negative for MRSA relative to the reference culture method, and $9 6 . 9 \%$ of the specimens positive for SA and $8 8 . 3 \%$ of the specimens negative for SA relative to the reference culture method.

Among these subjects with unknown antibiotic use, $9 7 . 0 \%$ (194/200) were successful on the first attempt with the Xpert MRSA/SA Assay. The remaining 6 gave indeterminate results on the first attempt (2 "INVALID", 3 "ERROR" and 1 "NO RESULT"). Of the 6 indeterminate on the first attempt, all gave a result on the second attempt.

Table 5.7c: MRSA/SA Performance in Subjects with Known Antibiotic Use (within 3 weeks of sample collection) vs. Reference Culture   
Culture   
  

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>MRSA+</td><td rowspan=1 colspan=1>SA+/MRSA-</td><td rowspan=1 colspan=1>Neg/No Growth</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>MRSA+</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>56</td></tr><tr><td rowspan=1 colspan=1>SA+/MRSA-</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>53</td></tr><tr><td rowspan=1 colspan=1>SA-</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>98</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>207</td></tr></table>

Positive Percent Agreement $( \mathrm { M R S A } { + } ) = 8 8 . 0 \%$ .a $9 5 \%$ Confidence Interval = 75.7-95.5

Negative Percent Agreement $( \mathrm { M R S A } { + } ) = 9 2 . 4 \%$ . $9 5 \%$ Confidence Interval $= 8 7 . 0 { - } 9 6 . 0$ EPY Positive Percent Agreement $( \mathrm { S A } { + } / \mathrm { M R S A } { + } ) = 9 5 . 2 \%$ .. $9 5 \%$ Confidence Interval $= 8 8 . 3$ - 98.7   
Negative Percent Agreement $( \mathrm { S A } + / \mathrm { M R S A } + ) = 7 6 . 4 \%$ $9 5 \%$ Confidence Interval $= 6 7 . 9 \cdot$ . 83.6

Among subjects with known antibiotic use within the 3 weeks prior to sample collection, the Xpert MRSA/SA SSTI Assay identified $8 8 . 0 \%$ of the specimens positive for MRSA and $9 2 . 4 \%$ of the specimens negative for MRSA relative to the reference culture method, and $9 5 . 2 \%$ of the specimens positive for SA and $7 6 . 4 \%$ of the specimens negative for SA relative to the reference culture method.

Among these subjects with antibiotic use, $9 6 . 1 \%$ (199/207) of these eligible specimens were successful on the first attempt with the Xpert MRSA/SA Assay. The remaining 8 gave indeterminate results on the first attempt (5 "INVALID" and 3 "ERROR"). Of the 8 indeterminate on the first attempt, all gave a result on the second attempt.

Empty Cassette Variants

For an isolate to be identified as MRSA positive with the Xpert MRSA/SA SSTI Assay, the test for spa must be positive as well as the test for mecA and SCCmec. An isolate that is positive for spa and SCCmec, but not mecA is reported SA because it is methicillinsensitive. This situation can occur when the portion of the SCCmec element carrying mecA is excised, but the ends of this mobile element remain in place, yielding a positive SCCmec signal. These isolates are sometimes referred to as "empty cassette variants" and are not uncommon in the clinical environment. The significance of these isolates is to potentially confound an assay for MRSA that does not detect the mecA gene directly. The Xpert MRSA/SA Assay was designed to correctly identify these variants as SA.

Among the eligible specimens included in the data analyses presented in this report, a total of 16 isolates fit the empty cassette profile resulting in positive spa and SCCmec test results, but no mecA detection $( \mathrm { C t } = 0 )$ as shown in Table 5.8. Fifteen of the 16 were verified MRSA true negative isolates relative to culture, and 14 of 16 were verified true positive SA isolates relative to culture. One isolate was identified as MRSA by culture and 2 isolates were both MRSA and SA negative by culture.

Table 5.8 : MRSA/SA SSTI Performance vs. Reference Culture - Empty Cassctte Variants   

<table><tr><td rowspan=2 colspan=1>Subject #</td><td rowspan=2 colspan=1>XpertResult</td><td rowspan=2 colspan=1>spa(Ct)</td><td rowspan=2 colspan=1>mecA(Ct)</td><td rowspan=2 colspan=1>SCCmec(Ct)</td><td rowspan=2 colspan=1>Culture</td><td rowspan=1 colspan=2>Xpert v. Culture</td></tr><tr><td rowspan=1 colspan=1>MRSA</td><td rowspan=1 colspan=1>SA</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>23.6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>26.0</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>TP</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>14.7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>16.5</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>TP</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>20.5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>34.0</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>TP</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>18.4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>21.0</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>TP</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>15.6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>28.4</td><td rowspan=1 colspan=1>MRSA</td><td rowspan=1 colspan=1>FN</td><td rowspan=1 colspan=1>TP</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>17.2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>31.6</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>TP</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>34.1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>35.6</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>FP</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>29.1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>33.0</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>TP</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>12.7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>23.5</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>TP</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>18.2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>27.6</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>TP</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>18.4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>22.0</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>TP</td></tr><tr><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>25.5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>27.7</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>TP</td></tr><tr><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>22.1</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>FP</td></tr><tr><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>26.0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>28.3</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>TP</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>23.9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>25.7</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>TP</td></tr><tr><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>19.9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>34.0</td><td rowspan=1 colspan=1>SA</td><td rowspan=1 colspan=1>TN</td><td rowspan=1 colspan=1>TP</td></tr></table>

# Carry-Over Contamination Study

A study was conducted to demonstrate that single-use, self-contained GeneXpert cartridges prevent carry-over contamination in negative samples run following very high positive samples in the same GeneXpert module. The study consisted of a negative sample processed in the same GeneXpert module immediately following a very high MRSA positive sample (roughly $1 0 ^ { 7 }$ CFU/test). This was repeated 20 times between 2 GeneXpert modules for a total of 42 runs. There was no evidence of any carry-over contamination. All 21 positive samples were correctly reported MRSA positive: SA positive. All 21 negative samples were correctly reported MRSA negative; SA negative.

# Reproducibility Study

A panel of 10 specimens with varying concentrations of SA, MRSA and Staphylococcus epidermidis (negative) were tested in duplicate on 10 different days at each of the three sites (10 specimens x 2 times/ day x 10 days x 3 sites). One lot of Xpert MRSA/SA kit was used at each of the 3 testing sites. Xpert MRSA/SA assays were performed according to the Xpert MRSA/SA procedure.

Table 5.9  Summary of Reproducibility Results   

<table><tr><td rowspan=1 colspan=1>Specimen ID</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>% Total Agreement</td></tr><tr><td rowspan=1 colspan=1>Neg (MSSE)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100% (60/60)</td></tr><tr><td rowspan=1 colspan=1>SA High Neg</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>90%(18/20)</td><td rowspan=1 colspan=1>96.7% (58/60)</td></tr><tr><td rowspan=1 colspan=1>SA Low Pos</td><td rowspan=1 colspan=1>90%(18/20)</td><td rowspan=1 colspan=1>95%(19/20)</td><td rowspan=1 colspan=1>75%(15/20)</td><td rowspan=1 colspan=1>86.6% (52/60)</td></tr><tr><td rowspan=1 colspan=1>SA Moderate Pos²</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>95%(19/20)</td><td rowspan=1 colspan=1>98.3% (59/60)</td></tr><tr><td rowspan=1 colspan=1>MRSA1 High Neg</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>90%(18/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>96.6% (58/60)</td></tr><tr><td rowspan=1 colspan=1>MRSA1 Low Pos1</td><td rowspan=1 colspan=1>85%(17/20)</td><td rowspan=1 colspan=1>70%(14/20)</td><td rowspan=1 colspan=1>65%(13/20))</td><td rowspan=1 colspan=1>73.3% (44/60)</td></tr><tr><td rowspan=1 colspan=1>MRSA1 Moderate Pos2</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>95%(18/20)</td><td rowspan=1 colspan=1>96.6% (58/60)</td></tr><tr><td rowspan=1 colspan=1>MRSA2 High Neg</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100% (60/60)</td></tr><tr><td rowspan=1 colspan=1>MRSA2 Low Pos1</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>95%(19/20)</td><td rowspan=1 colspan=1>98.3% (59/60)</td></tr><tr><td rowspan=1 colspan=1>MRSA2 Moderate Pos2</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>95%(19/20)</td><td rowspan=1 colspan=1>95%(19/20)</td><td rowspan=1 colspan=1>96.6% (58/60)</td></tr><tr><td rowspan=1 colspan=1>% Total Agreementby Site</td><td rowspan=1 colspan=1>97.5%(195/200)</td><td rowspan=1 colspan=1>95%(190/200)</td><td rowspan=1 colspan=1>90%(180/200)</td><td rowspan=1 colspan=1>94.2% (565/600)</td></tr></table>

Table 5.10 - Summary of Ct Value Results by Sample Level and Probe   

<table><tr><td colspan="3">SPC</td></tr><tr><td>Level</td><td>Mean Std Dev</td><td>%CV</td></tr><tr><td>MRSA1 High Neg</td><td>34.52 0.82</td><td>2.36</td></tr><tr><td>MRSA2 High Neg</td><td>34.46 0.85</td><td>2.46</td></tr><tr><td>Neg (MSSE)</td><td>34.44 0.90</td><td>2.62</td></tr><tr><td>SA High Neg</td><td>34.38 0.92</td><td>2.66</td></tr></table>

<table><tr><td colspan="3">Spa</td></tr><tr><td>Level Mean</td><td>Std Dev</td><td>%CV</td></tr><tr><td>MRSA1 Low Pos</td><td>32.96 0.8</td><td>2.44</td></tr><tr><td>MRSA2 Low Pos 31.05</td><td>0.69</td><td>2.21</td></tr><tr><td>SA Low Pos 33.91</td><td>0.8</td><td>2.35</td></tr></table>

<table><tr><td colspan="3">mecA</td></tr><tr><td>Level</td><td>Mean Std Dev</td><td>%CV</td></tr><tr><td>MRSA1 Low Pos</td><td>33.25 0.80</td><td>2.40</td></tr><tr><td>MRSA2 Low Pos</td><td>31.50 0.68</td><td>2.16</td></tr></table>

<table><tr><td colspan="2">SCCmec</td></tr><tr><td>Level</td><td>Mean Std Dev %CV</td></tr><tr><td>MRSA1 Low Pos</td><td>34.19 0.90 2.63</td></tr><tr><td>MRSA2 Low Pos</td><td>33.13 0.68 2.05</td></tr></table>

A second reproducibility study was performed using a panel of 4 specimens of (SA: 10X LoD, MRSA1: 10X LoD, MRSA2: 10X LoD, and Negative Control: Staphylococcus epidermidis). The panels were tested in duplicate on 10 different days at each of the three sites (4 specimens x 2 times/ day x 10 days x 3 sites). One lot of Xpert MRSA/SA SSTI Assay was used at each of the 3 testing sites. Xpert MRSA/SA assays were performed according to the Xpert MRSA/SA procedure. The correct results were obtained in 239 of 240 tests.

Table 5.11  Summary of Second Reproducibility Results   

<table><tr><td colspan="1" rowspan="1">Specimen ID</td><td colspan="1" rowspan="1">Site 1</td><td colspan="1" rowspan="1">Site 2</td><td colspan="1" rowspan="1">Site 3</td><td colspan="1" rowspan="1">TotalAgreement</td></tr><tr><td colspan="1" rowspan="1">Neg (MSSE)</td><td colspan="1" rowspan="1">100%(20/20)</td><td colspan="1" rowspan="1">100%(20/20)</td><td colspan="1" rowspan="1">100%(20/20)</td><td colspan="1" rowspan="1">100%(60/60)</td></tr><tr><td colspan="1" rowspan="1">SA Moderate Pos</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">(20/20)</td><td colspan="1" rowspan="1">(20/20)</td><td colspan="1" rowspan="1">(20/20)</td><td colspan="1" rowspan="1">(60/60)</td></tr><tr><td colspan="1" rowspan="1">MRSA1 Moderate Pos</td><td colspan="1" rowspan="1">100%(20/20)</td><td colspan="1" rowspan="1">100%(20/20)</td><td colspan="1" rowspan="1">100%(20/20)</td><td colspan="1" rowspan="1">100%(60/60)</td></tr><tr><td colspan="1" rowspan="1">MRSA2 Moderate Pos</td><td colspan="1" rowspan="1">100%(20/20)</td><td colspan="1" rowspan="1">100%(20/20)</td><td colspan="1" rowspan="1">95%(19/20)</td><td colspan="1" rowspan="1">98.3%(59/60)</td></tr><tr><td colspan="1" rowspan="1">% Total Agreement by Sitc</td><td colspan="1" rowspan="1">100%(80/80)</td><td colspan="1" rowspan="1">100%(80/80)</td><td colspan="1" rowspan="1">98.8%(79/80)</td><td colspan="1" rowspan="1">99.6%(239/240)</td></tr></table>

10X LoD

# Table 5.12 - Summary of Ct Value Results by Sample Level and Probe

<table><tr><td>SPC</td><td colspan="2"></td></tr><tr><td>Level</td><td>Mean Std Dev</td><td>%CV</td></tr><tr><td rowspan="3">MRSA1 Moderate Pos MRSA2 Moderate Pos SA Moderate Pos</td><td>35.72 1.87</td><td>5.24</td></tr><tr><td>36.29 2.66</td><td>7.34</td></tr><tr><td>34.55 1.19</td><td>3.44</td></tr><tr><td>NEG</td><td>34.45 1.06</td><td>3.09</td></tr></table>

<table><tr><td colspan="2">Spa</td></tr><tr><td>Level Mean</td><td>Std Dev %CV</td></tr><tr><td>MRSA1 Moderate Pos MRSA2 Moderate Pos SA Moderate Pos 30.59</td><td>29.52 1.30 4.40 28.91 1.03 3.57</td></tr></table>

<table><tr><td colspan="3">mecA</td></tr><tr><td>Level</td><td>Mean Std Dev</td><td>%CV</td></tr><tr><td>MRSA1 Moderate Pos MRSA2 Moderate Pos</td><td>29.78 1.28 29.32 1.24</td><td>4.29 4.22</td></tr></table>

<table><tr><td colspan="3">SCCmec</td></tr><tr><td>Level</td><td>Mean Std Dev</td><td>%CV</td></tr><tr><td>MRSA1 Moderate Pos MRSA2 Moderatc Pos</td><td>31.49 1.26 31.05 1.12</td><td>3.99 3.59</td></tr></table>

# Conclusions

The results of the nonclinical analytical and clinical performance studies summarized above demonstrate that the MRSA/ST SSTI Assay is as safe, as effective, and performs as well as or better than the predicate device.

# SEP 2 4 2008

Russel K. Enns, Ph.D.   
Senior Vice President   
Regulatory & Clinical Affairs,   
Quality System and Reimbursement Cepheid, Inc.   
904 Caribbean Drive   
Sunnyvale, CA 94089

Re: k080837 Trade/Device Name: XpertT™ MRSA/SA SSTI Assay Regulation Number: 21 CFR 866.1640 Regulation Name: Antimicrobial Susccptibility Test Powder Regulatory Class: Class II Product Code: NQX Dated: August 1, 2008 Received: August 4, 2008

Dear Dr. Enns:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at 240-276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Sall attoy

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

Enclosure

# 4.0 Indications for Use Statement

510(k) Number (if known): k080837

Devicc Name: Xpert MRSA/SA SSTI

Indications for Use:

The Cepheid Xpert MRSA/SA Skin and Soft Tissues Infection Assay (Xpert MRSA/SA SSTI Assay) performed in the GeneXpert $\textsuperscript { \textregistered }$ Dx System is a qualitative in vitro diagnostic test intended for the detection of Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) from skin and soft tissue infection swabs. The test utilizes automated real-time polymerase chain reaction (PCR) to detect MRSA/SA DNA. The Xpert MRSA/SA SSTI Assay is indicated for use in conjunction with other laboratory tests such as microbiology culture, and clinical data available to the clinician as an aid in the detection of MRSA/SA from skin and soft tissue infections. The Xpert MRSA/SA SSTI Assay is not intended to monitor treatment for MRSA/SA infections. Concomitant cultures for SA and MRSA are necessary to recover organisms for susceptibility testing or epidemiological typing. In a mixed culture containing MRSA/SA and other organisms (e.g. Gram negative bacilli, yeast), results can be false negative or variable depending on the concentration of MRSA/SA present, particularly if the concentration of MRSA/SA is close to the LoD of the assay.

Prescription Use X (Part 21 CFR 801 Subpart D)

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Division Sign-Off